NASDAQ:ATNF 180 Life Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $0.91 +0.04 (+4.60%) (As of 07/5/2022 03:50 PM ET) Add Compare Share Today's Range$0.85▼$0.9150-Day Range$0.81▼$2.1352-Week Range$0.79▼$11.20Volume981 shsAverage Volume306,110 shsMarket Capitalization$31.07 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media 180 Life Sciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,122.2% Upside$11.00 Price TargetShort InterestHealthy3.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.71 out of 5 starsMedical Sector837th out of 1,428 stocksPharmaceutical Preparations Industry418th out of 680 stocks 3.0 Analyst's Opinion Consensus Rating180 Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, 180 Life Sciences has a forecasted upside of 1,122.2% from its current price of $0.90.Amount of Analyst Coverage180 Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.31% of the outstanding shares of 180 Life Sciences have been sold short.Short Interest Ratio / Days to Cover180 Life Sciences has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 180 Life Sciences has recently decreased by 18.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield180 Life Sciences does not currently pay a dividend.Dividend Growth180 Life Sciences does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATNF. Previous Next 3.0 News and Social Media Coverage News Sentiment180 Life Sciences has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for 180 Life Sciences this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added 180 Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 180 Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders15.20% of the stock of 180 Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.20% of the stock of 180 Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share Ratio180 Life Sciences has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About 180 Life Sciences (NASDAQ:ATNF) Stock1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Read More ATNF Stock News HeadlinesJune 15, 2022 | markets.businessinsider.comThe Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid DataJune 14, 2022 | seekingalpha.com180 Life Sciences falls after updates on regulatory path for anti-fibrosis therapyJuly 5, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! June 14, 2022 | finance.yahoo.com180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s DiseaseMay 31, 2022 | finance.yahoo.com180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s DiseaseMay 2, 2022 | finance.yahoo.comREPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet RheumatologyApril 29, 2022 | finance.yahoo.com180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet RheumatologyMarch 31, 2022 | finance.yahoo.com180 Life Sciences Corp. (ATNF)July 5, 2022 | Tradewins (Ad)The Safest Option in Trades!If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! March 17, 2022 | proactiveinvestors.com180 Life Sciences Corp describes recent milestones with lead indication in Dupuytren’s diseaseFebruary 17, 2022 | finance.yahoo.com180 Life Sciences Corp. Forms Scientific Advisory BoardJanuary 31, 2022 | finance.yahoo.com180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to ShareholdersDecember 28, 2021 | finance.yahoo.com180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022December 15, 2021 | finance.yahoo.com180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver DiseasesDecember 12, 2021 | finance.yahoo.comInsider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More SharesDecember 10, 2021 | finance.yahoo.com180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of SharesDecember 6, 2021 | finance.yahoo.com180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial ResultsDecember 1, 2021 | nasdaq.com180 Life Sciences: Positive Data From Dupuytren’s Disease Study Could Be a Big Catalyst, Says AnalystNovember 22, 2021 | finance.yahoo.com180 Life Sciences Corp. Expands Patent PortfolioNovember 17, 2021 | nasdaq.com180 Life Sciences Corp.'s (NASDAQ:ATNF) stock has plunged to US$4.04, but insiders may have sold too soon at an even lower price of US$2.78November 3, 2021 | finance.yahoo.com180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business OfficerOctober 26, 2021 | finance.yahoo.com180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal MoleculesOctober 19, 2021 | benzinga.com180 Life Sciences Stock Bounces Off Support: What's Next?September 30, 2021 | finance.yahoo.com180 Life Sciences Corp. Continues To Expand Intellectual Property PortfolioSeptember 20, 2021 | finance.yahoo.comCelltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel IndicationsSeptember 15, 2021 | msn.comWhy 180 Life Sciences' Stock Is Trading Higher TodayAugust 24, 2021 | finance.yahoo.com180 Life Sciences Corp. Announces Closing of $15.0 Million Private PlacementSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATNF CUSIPN/A CIK1690080 Webwww.kblmerger.com Phone(650) 507-0669FaxN/AEmployees2Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/05/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+1,108.8%Consensus RatingHold Rating Score (0-4)2 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.92% Return on Assets-9.32% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book0.78Miscellaneous Outstanding Shares34,140,000Free Float28,954,000Market Cap$31.07 million OptionableNot Optionable Beta0.18 180 Life Sciences Frequently Asked Questions Should I buy or sell 180 Life Sciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 180 Life Sciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" 180 Life Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNF, but not buy additional shares or sell existing shares. View analyst ratings for 180 Life Sciences or view top-rated stocks. What is 180 Life Sciences' stock price forecast for 2022? 1 brokers have issued 1-year price targets for 180 Life Sciences' stock. Their ATNF stock forecasts range from $11.00 to $11.00. On average, they expect 180 Life Sciences' stock price to reach $11.00 in the next year. This suggests a possible upside of 1,108.8% from the stock's current price. View analysts' price targets for 180 Life Sciences or view top-rated stocks among Wall Street analysts. How has 180 Life Sciences' stock price performed in 2022? 180 Life Sciences' stock was trading at $3.90 at the start of the year. Since then, ATNF stock has decreased by 76.7% and is now trading at $0.91. View the best growth stocks for 2022 here. When is 180 Life Sciences' next earnings date? 180 Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for 180 Life Sciences. How were 180 Life Sciences' earnings last quarter? 180 Life Sciences Corp. (NASDAQ:ATNF) issued its quarterly earnings data on Monday, May, 16th. The company reported ($0.05) earnings per share for the quarter. View 180 Life Sciences' earnings history. Who are 180 Life Sciences' key executives? 180 Life Sciences' management team includes the following people: Dr. James N. Woody M.D., Ph.D., CEO & Director (Age 80, Pay $448.27k)Mr. Ozan Pamir C.F.A., Interim CFO & Sec. (Age 30, Pay $334.36k) (LinkedIn Profile)Mr. Quan Anh Vu, COO & Chief Bus. Officer (Age 50, Pay $372k)Dr. Jonathan B. Rothbard Ph.D., Chief Scientific Officer (Age 70, Pay $372.03k)Dr. Raphael Mechoulam Ph.D., Co-Founder & Member of Scientific Advisory BoardMr. Jason Assad, Director of IRProf. Jagdeep Nanchahal, Chief Medical Officer & Chairman of Clinical Advisory Board Who are some of 180 Life Sciences' key competitors? Some companies that are related to 180 Life Sciences include Applied Molecular Transport (AMTI), Nanobiotix (NBTX), MediciNova (MNOV), Gelesis (GLS), Anebulo Pharmaceuticals (ANEB), LumiraDx (LMDX), Otonomy (OTIC), Puma Biotechnology (PBYI), ESSA Pharma (EPIX), Enochian Biosciences (ENOB), RVL Pharmaceuticals (RVLP), Akouos (AKUS), Nabriva Therapeutics (NBRV), Actinium Pharmaceuticals (ATNM) and Actinium Pharmaceuticals (ATNM). View all of ATNF's competitors. What is 180 Life Sciences' stock symbol? 180 Life Sciences trades on the NASDAQ under the ticker symbol "ATNF." How do I buy shares of 180 Life Sciences? Shares of ATNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 180 Life Sciences' stock price today? One share of ATNF stock can currently be purchased for approximately $0.91. How much money does 180 Life Sciences make? 180 Life Sciences (NASDAQ:ATNF) has a market capitalization of $31.07 million. How many employees does 180 Life Sciences have? 180 Life Sciences employs 2 workers across the globe. How can I contact 180 Life Sciences? 180 Life Sciences' mailing address is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. The official website for 180 Life Sciences is www.kblmerger.com. The company can be reached via phone at (650) 507-0669 or via email at jason@180lifesciences.com. This page (NASDAQ:ATNF) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
